Arteritis

This phase II trial tests whether adding bosentan to standard steroid treatment helps people with giant cell arteritis (GCA) avoid relapses and reduce steroid use. About 40 adults with GCA will receive either bosentan plus steroids or steroids alone for 3 months, then be followed…

This study tests whether people with giant cell arteritis (GCA) can safely take steroids for only 8 weeks instead of the usual 26 weeks when also using the drug tocilizumab. About 178 participants will be randomly assigned to one of two treatment lengths. The goal is to see if th…

This phase 2 trial tests whether secukinumab, a drug that blocks IL-17A, can help people with active severe Takayasu arteritis achieve remission and stop taking steroids. About 52 participants will receive either secukinumab injections or standard care (like TNF inhibitors). The …

This study tests two new drugs, vunakizumab and ivarmacitinib, for people with active Takayasu arteritis (TAK), a rare disease that causes inflammation in large blood vessels. The trial will enroll 180 adults aged 18-70 whose disease is still active despite standard treatments. R…

This study looks at whether giving the drug rituximab early, when signs of the disease reappear in the blood, can prevent relapses in people with certain types of vasculitis (GPA and MPA). About 70 adults who have been on maintenance rituximab for at least 18 months will be rando…

This study tests whether adding pirfenidone, a drug used for lung and liver scarring, to standard treatment can improve blood vessel damage in people with Takayasu arteritis. About 92 adults aged 18-60 will receive either pirfenidone or a placebo for 6 months. The goal is to see …

This study will test a new type of PET/CT scanner, called Long-Axial Field-of-View (LAFOV), to see if it can provide clearer images of blood vessel inflammation in people with large vessel vasculitis (LVV). The scanner is more sensitive and can image the whole body faster, potent…

This study looks at how quickly the optic nerve sheath shrinks after starting steroids in people with giant cell arteritis, a condition that can cause blindness. Researchers will use eye ultrasounds and blood tests over two months in 60 newly diagnosed patients. The goal is to fi…

This study is building a biobank of blood samples and imaging data from 300 people with suspected inflammatory heart or autoimmune rheumatic diseases. Researchers aim to identify immune biomarkers that could predict major heart events like heart failure, stroke, or atrial fibrill…

This pilot study is investigating how quickly C-reactive protein (CRP), a key marker of inflammation, drops after starting steroid treatment in people newly diagnosed with giant cell arteritis. By measuring CRP levels daily, then weekly and monthly for up to a year, researchers h…

This study will use a special scan to look for B cells (a type of immune cell) in the blood vessels of 30 people with giant cell arteritis, a serious disease that can cause blindness or stroke. Current treatments rely on steroids, which have harsh side effects. If the scan works,…

This study will test whether a special ultrasound score, called OTUS, can accurately track disease activity in people with Takayasu arteritis, a rare condition that causes inflammation of the large arteries. Researchers will follow 100 patients with active disease, performing ult…

This study looks at whether two substances in the blood, IL-6 and MMP-7, can help doctors diagnose and predict the course of a rare lung disease in children. Researchers will measure these markers in 60 children with immune-mediated interstitial lung disease and compare them to h…

This study aims to see if there is a connection between two types of inflammatory conditions: one affecting the spine and joints (spondylarthritis) and another affecting blood vessels (giant cell arteritis) or muscles (polymyalgia rheumatica). Researchers will compare 10 adults w…

This study observes 80 adults with giant cell arteritis (GCA) affecting large arteries who are taking upadacitinib as part of their routine care. Researchers will collect data from medical records to see how many achieve remission at 24 weeks and track relapses over 2 years. No e…